Trials / Unknown
UnknownNCT02058771
Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
ULTIMATE: Utilising Lifemap to Investigate Malignant Arrhythmia ThErapy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- University Hospitals, Leicester · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
It is universally recognised that current methods for risk stratification of sudden cardiac death (SCD) are limited. A novel SCD risk marker, the Regional Restitution Instability Index (R2I2), measures the degree of heterogeneity in electrical restitution using data obtained from a standard 12 lead ECG acquired during an invasive electrophysiological study. In an ischaemic cardiomyopathy (ICM) cohort of 66 patients, an R2I2 of ≥1.03 identified subjects with a significantly higher risk of ventricular arrhythmia (VA) or death (43%) compared with those with an R2I2 \<1.03 (11%) (P=0.004). This study will use non-invasive techniques to acquire electrical restitution data: exercise and pharmacological stress, and will incorporate body surface potential mapping to develop a non-invasive and high-resolution form of R2I2. Suitable patients will be recruited into a prospective, observational study. HYPOTHESES: PRIMARY: 1. R2I2 is predictive of ventricular arrhythmia (VA) / SCD in patients with ICM. 2. The exercise stress protocol will create a dynamic range of heart rates that allows ECG quantification of electrical restitution heterogeneity that correlates with invasive R2I2 and is predictive of VA/SCD. The pharmacological stress protocol will create a dynamic range of heart rates that allows ECG based quantification of electrical restitution heterogeneity that correlates with invasive R2I2 and is predictive of VA/SCD. SECONDARY: 1. A high-resolution electrical map acquired using body surface potential mapping will correlate with R2I2 and these data can be included in the R2I2 calculation to improve its prediction of SCD/VA. 2. Serial measurement of R2I2 will produce consistent values.
Conditions
- Ischemic Cardiomyopathy
- Sudden Cardiac Death
- Implantable Defibrillator User
- Myocardial Infarction
- Arrhythmias, Cardiac
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2022-11-01
- Completion
- 2022-11-01
- First posted
- 2014-02-10
- Last updated
- 2020-11-09
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02058771. Inclusion in this directory is not an endorsement.